Sequentify

# High-Level Overview

Sequentify is a biotechnology company that develops library preparation solutions for Next-Generation Sequencing (NGS), addressing a critical bottleneck in genomic sample processing.[1][2] Founded in 2021 and based in Rehovot, Israel, the company has raised $7M in funding and focuses on making genomic testing faster, more affordable, and accessible at scale.[1][2]

The company's core mission is to eliminate barriers to widespread NGS adoption by simplifying and reducing the cost of sample preparation—the step that occurs before DNA sequencing hardware processes samples.[2] Sequentify serves the healthcare and personalized medicine sectors, offering targeted sequencing panels for oncology, screening applications, and infectious disease diagnostics.[1] By reducing both time and cost in the library preparation stage, the company aims to democratize genomic diagnostics, making it as routine and accessible as a blood test.[6]

# Origin Story

Sequentify was founded in 2021 in Rehovot, Israel, emerging at a moment when the genomic sequencing industry faced a critical challenge.[1] While sequencing hardware costs had declined dramatically due to platform improvements, the bottleneck had shifted upstream to the library preparation stage—the labor-intensive and expensive process of preparing DNA samples for sequencing.[2]

The company's founding addressed this specific pain point by developing innovative library-prep solutions that drastically reduce both cost and processing time.[1] This timing proved strategic: as sequencing became cheaper, laboratories worldwide needed solutions to handle sample preparation at scale without proportional cost increases. The company's early traction is evidenced by its ability to secure $7M in funding and establish partnerships with research institutions and clinical laboratories.[2]

# Core Differentiators

• InfiniSeq™ Workflow: Sequentify's proprietary technology enables pooling of samples into a single tube immediately after the first step, streamlining the entire targeted NGS library preparation process.[4]

• Cost and Speed Efficiency: The company's solutions are designed to be swift, effortless, and budget-friendly compared to traditional library preparation methods.[4]

• Platform Agnosticism: The InfiniSeq technology works independently of the sequencing platform used, providing flexibility for laboratories with different hardware investments.[4]

• Quality Accreditation: Sequentify holds ISO 13485 accreditation for manufacturing Next-Generation Sequencing kits, ensuring reliability for clinical and research applications.[2]

• Scalability Across Laboratory Sizes: The company's objective is to empower laboratories of all sizes—from manual processes to entry-level automation to high-end liquid handlers—to sequence samples efficiently at scale.[2]

• Integrated Bioinformatics: Sequentify provides not just kits but also a complete analysis pipeline for secondary data processing, including mapping, alignment, and noise reduction.[4]

# Role in the Broader Tech Landscape

Sequentify operates within the genomic democratization trend, where advances in sequencing technology are shifting from hardware innovation to workflow optimization.[2] The company is riding several converging forces: declining sequencing costs have made population-wide genomic testing economically feasible, but sample preparation remains a bottleneck preventing widespread clinical adoption.

The timing is critical because healthcare systems and research institutions increasingly recognize genomic testing as essential for precision medicine, oncology diagnostics, and infectious disease management.[1] By solving the library preparation problem, Sequentify enables the decentralization of NGS—allowing smaller laboratories and clinics to perform high-throughput sequencing without massive capital investment or specialized expertise.[2]

The company's influence extends beyond healthcare into agri-tech, animal science, and research applications, positioning it at the intersection of multiple high-growth markets.[2] As NGS becomes routine rather than specialized, companies that simplify upstream workflows will become critical infrastructure in the genomic testing ecosystem.

# Quick Take & Future Outlook

Sequentify is well-positioned to capture significant market share as genomic testing transitions from specialized research to routine clinical diagnostics. The company's focus on reducing friction in sample preparation—rather than competing in the crowded sequencing hardware space—represents a smart market positioning strategy.

Looking ahead, Sequentify's growth will likely depend on expanding its panel offerings across disease areas, scaling manufacturing capacity, and building distribution partnerships globally.[2] As regulatory frameworks for genomic diagnostics mature and reimbursement improves, demand for simplified, cost-effective library preparation solutions will accelerate. The company's early focus on clinical applications and quality accreditation positions it to capture this opportunity as genomic testing becomes as routine as traditional laboratory diagnostics.